BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716]
URL: https://www.wjgnet.com/1007-9327/full/v27/i44/7716.htm
Number Citing Articles
1
Chin-Chia Wu, Chuan-Yin Fang, Ben-Hui Yu, Chun-Ming Chang, Ta-Wen Hsu, Chung-Lin Hung, Shih-Kai Hung, Wen-Yen Chiou, Jui-Hsiu Tsai. Long-Term Usage of Proton Pump Inhibitors Associated with Prognosis in Patients with Colorectal CancerCancers 2023; 15(21): 5304 doi: 10.3390/cancers15215304
2
Soo Hee Jeong, Lara Molloy, Edmond Ang, Nuala Helsby. Re-thinking the possible interaction between proton pump inhibitors and capecitabineCancer Chemotherapy and Pharmacology 2022; 90(5): 381 doi: 10.1007/s00280-022-04473-9
3
Elżbieta Wojaczyńska, Jacek Wojaczyński. Sulfoxides in medicineCurrent Opinion in Chemical Biology 2023; 76: 102340 doi: 10.1016/j.cbpa.2023.102340
4
Wan-Ying Lin, Shih-Syuan Wang, Yi-No Kang, Andrea S. Porpiglia, Yu Chang, Chin-Hsuan Huang, Ronak Bhimani, Eahab Abdul-Lattif, Muneeba Azmat, Tsu-Hsien Wang, Yu-Shiuan Lin, Yu-Cheng Chang, Kuan-Yu Chi. Do proton pump inhibitors affect the effectiveness of chemotherapy in colorectal cancer patients? A systematic review with meta-analysisFrontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1048980
5
Khaled A. N. Abusharkh, Ferah Comert Onder, Venhar Çınar, Zuhal Hamurcu, Bulent Ozpolat, Mehmet Ay. A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cellsMedical Oncology 2024; 41(8) doi: 10.1007/s12032-024-02427-0
6
Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, Karine Le Malicot, David Tougeron, Véronique Lorgis, Véronique Guerin-Meyer, Vincent Bourgeois, David Malka, Thomas Aparicio, Matthieu Baconnier, Valérie Lebrun-Ly, Joëlle Egreteau, Faïza Khemissa Akouz, Magali Terme, Côme Lepage, Valérie Boige. First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)Cancers 2024; 16(8): 1515 doi: 10.3390/cancers16081515
7
Francisco Cezar Aquino de Moraes, Estella Aparecida de Laia, Vitor Kendi Tsuchiya Sano, Aline Gabriele Etur dos Santos, Caroline R M Pereira, Rommel Mario Rodríguez Burbano. A systematic review and meta-analysis of users versus non-users: unveiling the influence of proton pump inhibitors on capecitabine efficacy in colorectal cancerExpert Review of Clinical Pharmacology 2025; 18(1-2): 67 doi: 10.1080/17512433.2024.2443183
8
Masaya Takahashi, Katsuyuki Takahashi, Kanae Takahashi, Daichiro Fujiwara, Kaori Ito, Hirotake Yamase, Kaito Yamashiro, Hajime Asano, Naoki Yabuta, Tadafumi Hoshida, Takenao Koseki, Masahito Shibano, Kanako Tsukada, Yasuhiko Takata, Yuika Komatsu, Satoshi Noda, Kohei Hashimoto, Toru Otori. A multicenter retrospective study evaluating the effect of proton pump inhibitors on adjuvant tegafur-uracil/leucovorin efficacy for stage II–III colorectal cancerScientific Reports 2025; 15(1) doi: 10.1038/s41598-025-94105-y